Floor E Aleva1, Lucas W L M Voets2, Sami O Simons2, Quirijn de Mast3, André J A M van der Ven3, Yvonne F Heijdra2. 1. Department of Respiratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: floor.aleva@radboudumc.nl. 2. Department of Respiratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. 3. Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Abstract
BACKGROUND: Patients with COPD experience episodes of increased inflammation, so-called acute exacerbations of COPD (AE-COPD). In 30% of AE-COPD cases, no clear cause is found. Since there is well-known cross talk between inflammation and thrombosis, the objectives of this study were to determine the prevalence, embolus localization, clinical relevance, and clinical markers of pulmonary embolism (PE) in unexplained AE-COPD. METHODS: A systematic search was performed using MEDLINE and EMBASE platforms from 1974 to October 2015. Prospective and cross-sectional studies that included patients with AE-COPD and used pulmonary CT-angiography for diagnosis of PE were included. RESULTS: The systematic search resulted in 1,650 records. The main reports of 22 articles were reviewed, and 7 studies were included. The pooled prevalence of PE in unexplained AE-COPD was 16.1% (95% CI, 8.3%-25.8%) in a total of 880 patients. Sixty-eight percent of the emboli found were located in the main pulmonary arteries, lobar arteries, or interlobar arteries. Mortality and length of hospital admission seemed to be increased in patients with unexplained AE-COPD and PE. Pleuritic chest pain and cardiac failure were more frequently reported in patients with unexplained AE-COPD and PE. In contrast, signs of respiratory tract infection was less frequently related to PE. CONCLUSIONS: PE is frequently seen in unexplained AE-COPD. Two-thirds of emboli are found at locations that have a clear indication for anticoagulant treatment. These findings merit clinical attention. PE should receive increased awareness in patients with unexplained AE-COPD, especially when pleuritic chest pain and signs of cardiac failure are present, and no clear infectious origin can be identified.
BACKGROUND:Patients with COPD experience episodes of increased inflammation, so-called acute exacerbations of COPD (AE-COPD). In 30% of AE-COPD cases, no clear cause is found. Since there is well-known cross talk between inflammation and thrombosis, the objectives of this study were to determine the prevalence, embolus localization, clinical relevance, and clinical markers of pulmonary embolism (PE) in unexplained AE-COPD. METHODS: A systematic search was performed using MEDLINE and EMBASE platforms from 1974 to October 2015. Prospective and cross-sectional studies that included patients with AE-COPD and used pulmonary CT-angiography for diagnosis of PE were included. RESULTS: The systematic search resulted in 1,650 records. The main reports of 22 articles were reviewed, and 7 studies were included. The pooled prevalence of PE in unexplained AE-COPD was 16.1% (95% CI, 8.3%-25.8%) in a total of 880 patients. Sixty-eight percent of the emboli found were located in the main pulmonary arteries, lobar arteries, or interlobar arteries. Mortality and length of hospital admission seemed to be increased in patients with unexplained AE-COPD and PE. Pleuritic chest pain and cardiac failure were more frequently reported in patients with unexplained AE-COPD and PE. In contrast, signs of respiratory tract infection was less frequently related to PE. CONCLUSIONS: PE is frequently seen in unexplained AE-COPD. Two-thirds of emboli are found at locations that have a clear indication for anticoagulant treatment. These findings merit clinical attention. PE should receive increased awareness in patients with unexplained AE-COPD, especially when pleuritic chest pain and signs of cardiac failure are present, and no clear infectious origin can be identified.
Authors: Tadahiro Goto; Yuichi J Shimada; Mohammad Kamal Faridi; Carlos A Camargo; Kohei Hasegawa Journal: J Gen Intern Med Date: 2018-06-08 Impact factor: 5.128
Authors: David Jiménez; Alvar Agustí; Eva Tabernero; Luis Jara-Palomares; Ascensión Hernando; Pedro Ruiz-Artacho; Gregorio Pérez-Peñate; Agustina Rivas-Guerrero; María Jesús Rodríguez-Nieto; Aitor Ballaz; Ramón Agüero; Sonia Jiménez; Myriam Calle-Rubio; Raquel López-Reyes; Pedro Marcos-Rodríguez; Deisy Barrios; Carmen Rodríguez; Alfonso Muriel; Laurent Bertoletti; Francis Couturaud; Menno Huisman; José Luis Lobo; Roger D Yusen; Behnood Bikdeli; Manuel Monreal; Remedios Otero Journal: JAMA Date: 2021-10-05 Impact factor: 56.272